An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942)

← catalyst calendar

NCT03897881 · readout in 2,294 d

Sponsored by ModernaTX, Inc. (industry) · MRNA — their whole pipeline →. With Merck Sharp & Dohme LLC.

Phase

Phase 2

Status

Active, not recruiting

Study type

Interventional

Design

Randomized · None · Treatment

Enrollment

267actual

Sites

Countries

Australia, United States

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2019-07-18

actual

When the study began enrolling

Primary completion

2032-11-30

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

2032-11-30

estimated

The whole study's end, after follow-up

First posted

2019-04-01

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2025-12-03

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Melanoma

Interventions

Drug: mRNA-4157
Biological: Pembrolizumab

Primary outcome

what the primary-completion date above is the date OF

Recurrence-Free Survival (RFS), Assessed Using Radiological Imaging

measured Up to 7 years

Publications

PMID 42223134 — linked by the registry
PMID 38246194 — linked by the registry

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · MRNA's whole pipeline · Catalyst calendar · Every registered study · What changed